Merck (MRK) Income from Non-Controlling Interests (2009 - 2026)
Merck's (MRK) quarterly Income from Non-Controlling Interests came in at -$2.0 million in Q2 2026, down 300.0% year-over-year from $1.0 million in Q2 2025, and up 33.33% quarter-over-quarter from -$3.0 million in Q1 2026.
Analysis
Merck (MRK) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Income from Non-Controlling Interests for 18 consecutive years, with -$2.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 300.0% year-over-year to -$2.0 million in Q2 2026; TTM through Jun 2026 was -$4.0 million, a 133.33% decrease from a year earlier, with the FY2025 full-year figure at $9.0 million, down 43.75% from the prior year.
- Income from Non-Controlling Interests was -$2.0 million for Q2 2026 at Merck, up from -$3.0 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $6.0 million in Q2 2024 and troughed at -$3.0 million in Q1 2022.
- A 5-year average of $2.3 million and a median of $3.0 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests jumped 400.0% in 2022 and sank 300.0% in 2026, its largest moves.
- Over 5 years, Income from Non-Controlling Interests stood at $1.0 million in 2022, then jumped by 400.0% to $5.0 million in 2023, then tumbled by 80.0% to $1.0 million in 2024, then slumped by 200.0% to -$1.0 million in 2025, then sank by 100.0% to -$2.0 million in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$2.0 million (Q2 2026), -$3.0 million (Q1 2026), and -$1.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 10.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -1.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 39.52 Mn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.00 Mn |
| Mar 31, 2026 | -3.00 Mn |
| Dec 31, 2025 | -1.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 6.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Jun 30, 2023 | 3.00 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | -3.00 Mn |
| Dec 31, 2021 | 4.00 Mn |
| Sep 30, 2021 | 4.00 Mn |
| Jun 30, 2021 | 1.00 Mn |